Identify At-Risk Drug Products and Ensure Compliance Before Nitrosamines Deadline
Risk evaluation of products containing chemically synthesized APIs must be done to assess adherence to nitrosamine regulations.
Marketing Authorization Holders (MAHs) must perform a risk evaluation of their medicinal products containing chemically synthesized Active Pharmaceutical Ingredients (APIs) to assess adherence to nitrosamine regulations. The risk evaluation of all products must be concluded by March 31, 2021, at the latest.
Find out how ProPharma experts expediently satisfied a request for a risk assessment essential to meeting nitrosamine regulatory requirements.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...